Subscribe To
CRDL / Cardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditis
Content Topics
Cardiol
Therapeutics
Kicks
Multi
Center
Phase
Pilot
Study
Multi center
Cardiolrx
Treatment
Recurrent
Pericarditis
Stock
CRDL
CRDL News
By Proactive Investors
November 1, 2023
Cardiol Therapeutics reaches new milestone in Phase II study for recurrent pericarditis
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open- more_horizontal
By Proactive Investors
October 10, 2023
Cardiol Therapeutics says study results show positive effects of subcutaneously administered cannabidiol
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has reported positive study results showing that cannabidiol, the active pharmaceutical ingredient in the more_horizontal
By Zacks Investment Research
September 27, 2023
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
Here we discuss some reasons why investing in Cardiol Therapeutics (CRDL) stock now may turn out to be a prudent move. more_horizontal
By Newsfile Corp
September 26, 2023
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinica more_horizontal
By Zacks Investment Research
August 16, 2023
Cardiol Therapeutics Inc. (CRDL) Upgraded to Buy: Here's What You Should Know
Cardiol Therapeutics Inc. (CRDL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This more_horizontal
By Proactive Investors
May 23, 2023
Cardiol Therapeutics earns higher price target from broker as it ends 1Q with sufficient cash to advance CardioRx candidate
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has retained a ‘Buy' rating with an increased price target from Canaccord Genuity (TSX:CF, LSE:CF) an more_horizontal
By Proactive Investors
March 29, 2023
Cardiol Therapeutics offers an update on operations as it advances the development of its lead drug candidate CardiolRx
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors in a year-end 2022 update on operations that the life sciences compan more_horizontal
By Proactive Investors
March 7, 2023
Cardiol Therapeutics says new study results highlight the cardioprotective effects of cannabidiol
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said that new study results have demonstrated the cardioprotective effects of pharmaceutically manufactur more_horizontal